Steven Gore, MD | Authors


Dr. Steven Gore on Potential Negative Effects of Further Research into Azanucleoside Combinations

October 28, 2015

Steven D. Gore, MD, director of Hematologic Malignancies at Yale Cancer Center, talks about the risk of constantly testing azanucleoside combinations without significant results. Gore says that testing azanucleoside combinations that are not well planned may cause the medical community to overlook an effective combination due to fatigue of constant testing.